Is Thymosin Alpha-1 Legal in Florida?
HealthRX.com
No FDA approval, and no Florida rule is stated on this page
At a glance
- FDA approval / None; no US marketing application exists [1]
- State-licensed pharmacies and physicians / In none of the three interim-policy categories, list updated May 14, 2026 [2]
- Outsourcing facilities / Category 3, nominated without adequate support [4]
- Safety-risk table / Nominated but withdrawn; FDA's immunogenicity concerns remain posted [5]
- Advisory committee vote / 4 yes, 17 no, December 4, 2024 [3]
- Approved in / Italy, India, Hong Kong (Zadaxin) [1]
The short answer
Thymosin alpha-1 (thymalfasin) has no US marketing approval: a Drugs@FDA search found no application for it, and its four US orphan drug designations are a separate process, not an approval [1]. Zadaxin, the finished 1.6 mg injection sold outside the US, is not interchangeable with bulk peptide powder [1].
What the federal compounding rules say
FDA says state-licensed pharmacies and physicians may compound only with bulk substances that meet a USP or NF monograph, are components of FDA-approved drugs, or appear on FDA's list of bulk substances that can be used in compounding [6]. Thymosin alpha-1 has no FDA-approved product in the US [1], and FDA has proposed not adding it to the bulk-substances list [3].
FDA's interim policy places nominated substances in three categories. FDA says it does not intend to act against compounders using category 1 substances when the guidance conditions are met [6]. Thymosin alpha-1 is in none of the three categories on the list for state-licensed pharmacies and physicians, updated May 14, 2026, so the category 1 policy does not apply to it [2]. On the separate list for outsourcing facilities, updated March 21, 2025, it is in category 3, nominated without adequate support [4].
The safety-risk listing and the advisory committee vote
FDA's page on bulk substances that may present significant safety risks lists thymosin alpha-1 in the nominated-but-withdrawn table: it had been in category 2 and came off because the nominators withdrew [5]. FDA's concerns are still posted there, including significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [5].
On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate. Members who voted no cited no compelling evidence of clinical effectiveness and safety [3]. Thymosin alpha-1 is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [7].
Where thymosin alpha-1 is approved
FDA's December 2024 review lists authorizations in Italy, where Zadaxin is an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1]. Two reviews by authors tied to the Zadaxin developer put the number of approving countries at more than 30 in 2007 and over 35 in 2009 [8][9]. A foreign approval is not a US approval.
Does Florida law add anything?
The federal records above describe FDA and HHS status only. They do not address Florida state law, and this page does not state a Florida-specific legal status for thymosin alpha-1.
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
Can a US compounding pharmacy prepare thymosin alpha-1?
Has FDA flagged thymosin alpha-1 as a safety risk?
Is thymosin alpha-1 banned in sport?
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration. FDA review of thymosin alpha-1 (December 2024). FDA document 183820
- U.S. Food and Drug Administration. List of bulk drug substances for state-licensed pharmacies and physicians (interim policy categories). FDA document 94155
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee, December 4, 2024. FDA document 185642
- U.S. Food and Drug Administration. List of bulk drug substances for outsourcing facilities (interim policy categories). FDA document 94164
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA.
- U.S. Department of Health and Human Services. Peptide enforcement discretion policy, Appendix B. HHS policy appendix
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 Prohibited List